BROOKE HOLDEN: Open Payments
NPI 1598205320 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$964 in 32 payments from 11 companies in 2025. Trend: 2023 $1,974 · 2024 $1,478 · 2025 $964
Food & beverage: $866Education: $98
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $233 |
| Gilead Sciences, Inc. | 10 | $213 |
| Lilly USA, LLC | 5 | $175 |
| SANOFI-AVENTIS U.S. LLC | 1 | $121 |
| Janssen Scientific Affairs, LLC | 1 | $63 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $38 |
| Dexcom, Inc. | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
Products named: TREMFYA, ZEPBOUND, TZIELD, OMVOH, XIFAXAN, Dexcom G6 Transmitter, EOHILIA, ZENPEP.
Industry payments across NY — which companies pay providers there.
